EudraCT Nr.: 2010–020746-98

Protocol Nr.: 77557

Protocol name: An open-label phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from preserved travoprost 0.004% eye drops to preservative free tafluprost 0.0015% eye drops

Sponsor: Santen Oy

The above mentioned study was approved by BfArM on 22 Sept 2010. The study was about to start in Germany in October 2010.

Just before the study start Santen Oy got advance information that the comparative agent in this study (Travatan®, containing BAK) would be withdrawn in Europe by the marketing authorization holder Alcon in January-February 2011.

Based on the fact that the comparative agent was no more available, the study as cancelled before start of patient enrollment.

Study result information: not applicable